Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Malignant mesothelioma (MM) is an aggressive tumor arising primarily from pleural or peritoneal cavities, which is caused by asbestos exposure after long latency. One of the most frequently mutated genes detected in MM cells is the neurofibromatosis type 2 (NF2) tumor suppressor gene which is located at chromosome 22q12. The NF2 gene encodes Merlin, an ERM (Ezrin/Radixin/Moesin) protein. The underphosphorylated form of Merlin is active and acts as a tumor suppressor by regulating several distinct cellular signaling pathways. One of the downstream pathways regulated by Merlin is the Hippo signaling pathway, which is conserved from Drosophila to mammalian cells and plays important roles in organ size control and cancer development. Recent studies have identified alterations of the components in the Hippo signaling cascade in MM cells, including overexpression of Yes‐associated protein (YAP) and inactivation of large tumor suppressor homolog 2 (LATS2). Dysregulation of the Merlin‐Hippo signaling cascade is one of the frequent and key events of MM cell development and/or progression. Thus, a strategy to normalize this signaling cascade may be the rationale for developing a new target therapy against MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065
Organizing the cell cortex: the role of ERM proteins
Fehon, R. G., McClatchey, A. I., & Bretscher, A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2866 · Cited by 1,044
Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma
Xu, M. Z., Yao, T., Lee, N. P. Y., Ng, I. O. L., Chan, Y., Zender, L., Lowe, S. W., Poon, R. T. P., & Luk, J. M. (2009) · Cancer · doi:10.1002/cncr.24495 · Cited by 528
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Curto, M., Cole, B. K., Lallemand, D., Liu, C.-H., & McClatchey, A. I. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703010 · Cited by 363
Rac1 GTPase: A “Rac” of All Trades
Bosco, E. E., Mulloy, J. C., & Zheng, Y. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8552-x · Cited by 350
Cited by
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
The Hippo Signaling Pathway in Development and Disease
Zheng, Y., & Pan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.003 · Cited by 867
“Loss-of-function NF2 mutations are also observed in 19%–50% of malignant mesothelioma (Murakami et al., 2011; Sekido, 2011), 18%–22% of renal cell carcinoma (RCC) (Mehra et al.”
BackgroundTargeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Schwannomas and Their Pathogenesis
Hilton, D. A., & Hanemann, C. O. (2014) · Brain Pathology · doi:10.1111/bpa.12125 · Cited by 309
Metadata
- Authors
- Sekido, Y.
- Venue
- Pathology International
- Publisher
- Wiley
- Published
- 2011-05-02
- Volume
- 61
- Issue
- 6
- Pages
- 331-344
- ISSN
- 1320-5463 (ISSN-L)
- 1440-1827
- OpenAlex
- W1606625034
- Cited by
- 87
- References
- 10
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.